tbuckley/cabot-search huggingface dataset:
Abstract 9802: Social Determinants of Health and Cardiovascular Risk Among Adults with Diabetes: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study
Authors: Lisa Zhang, Evgeniya Reshetnyak, Laura Pinheiro, Doyle M Cummings, April P Carson, Raegan W Durant, Gargya Malla, Monika Safford
Journal: Circulation (2021)

Introduction: Social determinants of health (SDOH) have been associated with diabetes risk; however, their association with cardiovascular disease (CVD) events in individuals with diabetes is unknown. We hypothesized that as the number of SDOH among individuals with diabetes increased, the risk of CVD events would also increase. Methods: The REGARDS study is a national, biracial cohort of 30,239 individuals ≥45 years old recruited in 2003-7. We included 6,322 participants with diabetes at baseline, defined as healthcare professional diagnosis, diabetes medication use, or blood glucose values (fasting ≥126 or random ≥200 mg/dl). The outcome was CVD events, a composite defined as expert adjudicated myocardial infarction (MI), stroke, or fatal coronary heart disease (CHD) with follow up through 2018. Guided by the Healthy People 2030 framework, we included 5 SDOH significantly associated with CVD events: &lt; high school education, annual household income &lt;$35,000, residing in a zip code with ≥25% poverty, no health insurance, and social isolation from friends/family. We used Cox proportional hazard models to examine associations between number of SDOH (0, 1, or ≥2) and the composite endpoint and each individual endpoint separately, adjusting for demographics, medical conditions, health status, and physiological factors. Results: The mean age was 66 ± 9 years, 53% were female, and 58% were Black. In a fully adjusted model, the presence of &gt; 2 SDOH significantly increased the risk of CVD events (HR 1.17 [95% CI 1.01-1.36]) (Figure). However, there was no association for MI, an association for stroke, and a graded association for fatal CHD (1.44 [1.07-1.93] for one SDOH; 1.64 [1.20-2.23] for &gt; 2 SDOH). Conclusions: Having ≥2 SDOH was independently associated with an increased risk of CVD events in individuals with diabetes, a finding driven by stroke and fatal CHD. Identifying individuals with diabetes who have ≥2 SDOH may help detect those at higher risk for stroke and CHD death.
Synchronized cluster firing, a distinct form of sensory neuron activation, drives spontaneous pain
Authors: Qin Zheng, Wenrui Xie, Debora D. Lückemeyer, Mark Lay, Xue-Wei Wang, Xintong Dong, Nathachit Limjunyawong, Yaqing Ye, Feng-Quan Zhou, Judith A. Strong, Jun-Ming Zhang, Xinzhong Dong
Journal: Neuron (2021)
TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment
Authors: Shusuke Kawashima, Takashi Inozume, Masahito Kawazu, Toshihide Ueno, Joji Nagasaki, Etsuko Tanji, Akiko Honobe, Takehiro Ohnuma, Tatsuyoshi Kawamura, Yoshiyasu Umeda, Yasuhiro Nakamura, Tomonori Kawasaki, Yukiko Kiniwa, Osamu Yamasaki, Satoshi Fukushima, Yuzuru Ikehara, Hiroyuki Mano, Yutaka Suzuki, Hiroyoshi Nishikawa, Hiroyuki Matsue, Yosuke Togashi
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Patients with cancer benefit from treatment with immune checkpoint inhibitors (ICIs), and those with an inflamed tumor microenvironment (TME) and/or high tumor mutation burden (TMB), particularly, tend to respond to ICIs; however, some patients fail, whereas others acquire resistance after initial response despite the inflamed TME and/or high TMB. We assessed the detailed biological mechanisms of resistance to ICIs such as programmed death 1 and/or cytotoxic T-lymphocyte-associated protein 4 blockade therapies using clinical samples. Methods We established four pairs of autologous tumor cell lines and tumor-infiltrating lymphocytes (TILs) from patients with melanoma treated with ICIs. These tumor cell lines and TILs were subjected to comprehensive analyses and in vitro functional assays. We assessed tumor volume and TILs in vivo mouse models to validate identified mechanism. Furthermore, we analyzed additional clinical samples from another large melanoma cohort. Results Two patients were super-responders, and the others acquired resistance: the first patient had a non-inflamed TME and acquired resistance due to the loss of the beta-2 microglobulin gene, and the other acquired resistance despite having inflamed TME and extremely high TMB which are reportedly predictive biomarkers. Tumor cell line and paired TIL analyses showed high CD155, TIGIT ligand, and TIGIT expression in the tumor cell line and tumor-infiltrating T cells, respectively. TIGIT blockade or CD155-deletion activated T cells in a functional assay using an autologous cell line and paired TILs from this patient. CD155 expression increased in surviving tumor cells after coculturing with TILs from a responder, which suppressed TIGIT + T-cell activation. Consistently, TIGIT blockade or CD155-deletion could aid in overcoming resistance to ICIs in vivo mouse models. In clinical samples, CD155 was related to resistance to ICIs in patients with melanoma with an inflamed TME, including both primary and acquired resistance. Conclusions The TIGIT/CD155 axis mediates resistance to ICIs in patients with melanoma with an inflamed TME, promoting the development of TIGIT blockade therapies in such patients with cancer.
Resilience-based Integrated IBD Care Is Associated With Reductions in Health Care Use and Opioids
Authors: Laurie Keefer, Ksenia Gorbenko, Tina Siganporia, Laura Manning, Stacy Tse, Anthony Biello, Ryan Ungaro, Louis J. Cohen, Benjamin L. Cohen, Marla C. Dubinsky
Journal: Clinical Gastroenterology and Hepatology (2021)

Integrated inflammatory bowel disease (IBD) care is effective but not routinely implemented. Validated methods that simultaneously address mind and body targets such as resilience may improve access and outcomes. We describe the development and implementation of the GRITT method and its impact on resilience, health care utilization (HCU), and opioid use in IBD.Consecutive patients from an academic IBD center were evaluated for low resilience on the basis of provider referral. Low resilience patients were invited to participate in the GRITT program. Primary outcome was % reduction in HCU. Secondary outcomes were change in resilience and corticosteroid and opioid use. Patients were allocated into 2 groups for analysis: GRITT participants (GP) and non-participants (NP). Clinical data and HCU in the year before enrollment were collected at baseline and 12 months. One-way repeated measures multivariate analysis of covariance evaluated group × time interactions for the primary outcome. Effect size was calculated for changes in resilience over time.Of 456 screened IBD patients 394 were eligible, 184 GP and 210 NP. GP had greater reduction in HCU than NP: 71% reduction in emergency department visits, 94% reduction in unplanned hospitalizations. There was 49% reduction in opioid use and 73% reduction in corticosteroid use in GP. Resilience increased by 27.3 points (59%), yielding a large effect size (d = 2.4).Mind-body care that focuses on building resilience in the context of IBD care may be a novel approach to reduce unplanned HCU and opioid use, but large, multicenter, randomized controlled trials are needed.
Identification of a Conserved Intracellular Loop (CIL) Structure That Scaffolds PIP3 to Amplify Oncogenic Signaling during Malignant B-Cell Transformation
Authors: Jaewoong Lee, Mark E. Robinson, Ning Ma, Teresa Sadras, Kadriye Nehir Cosgun, Lai N. Chan, Kohei Kume, Andrei Thomas-Tikhonenko, David M. Weinstock, Michael S. Diamond, Nagarajan Vaidehi, Markus Müschen
Journal: Blood (2021)
Gene Expression Analysis of CML Patients across the Age Spectrum
Authors: Minyoung Youn, Stephanie M. Smith, Alex Gia Lee, Hee-Don Chae, Elizabeth Spiteri, Jason Erdmann, Ilana Galperin, Lara C. Murphy, Michele Donato, Parveen Abidi, Henrique Bittencourt, Norman J. Lacayo, Gary Dahl, Catherine Aftandilian, Kara L. Davis, Jairo A. Matthews, Steven M. Kornblau, Min Huang, Nathan Sumarsono, Michele Redell, Cecilia H. Fu, I-Ming L Chen, Todd A. Alonzo, Elizabeth A. Eklund, Jason Gotlib, Purvesh Khatri, Alejandro Sweet-Cordero, Nobuko Hijiya, Kathleen M. Sakamoto
Journal: Blood (2021)
Exploiting Transcription-Replication Conflicts As a Novel Therapeutic Intervention in Multiple Myeloma
Authors: Laure Dutrieux, Yea-Lih Lin, Malik Lutzmann, Guilhem Requirand, Nicolas Robert, Laure Vincent, Guillaume Cartron, Charles Herbaux, Raphael Rodriguez, Michel Cogne, Philippe Pasero, Jerome Moreaux
Journal: Blood (2021)
Outcome after Inotuzumab Ozogamicin for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Extramedullary Disease
Authors: Sabine Kayser, Chiara Sartor, Marlise R. Luskin, Jonathan Webster, Fabio Giglio, Nydia Panitz, Andrew M. Brunner, Matthias Fante, Christoph Lutz, Daniel Wolff, Anthony D. Ho, Mark Levis, Richard F. Schlenk, Cristina Papayannidis
Journal: Blood (2021)
Defining New Reference Intervals for Serum Free Light Chains in Individuals with Reduced Kidney Function: Results of the Population- Based on Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM) Study
Authors: Thorir Einarsson Long, Olafur Skuli Indridason, Runolfur Palsson, Sæmundur Rögnvaldsson, Thorvardur Jon Love, Sigrun Thorsteinsdottir, Ingigerdur Solveig Sverrisdottir, Brynjar Vidarsson, Pall Torfi Onundarson, Bjarni Agnar Agnarsson, Margret Sigurdardottir, Ingunn Thorsteinsdottir, Isleifur Olafsson, Asdis Rosa Thordardottir, Elias Eythorsson, Asbjorn Jonsson, Gauti Gislason, Andri Olafsson, Hlif Steingrimsdottir, Petros Kampanis, Malin Hultcrantz, Brian G.M. Durie, Stephen Harding, Ola Landgren, Sigurdur Yngvi Kristinsson
Journal: Blood (2021)
Abstract 8935: A Study of CMS-Mandated Online Tools for Comparing the Prices of Outpatient Cardiovascular Diagnostic Studies
Authors: Robert Tungate, Parveen K Garg
Journal: Circulation (2021)

Objectives: To assess the tools the US Centers for Medicare &amp; Medicaid Services (CMS) price transparency mandate provides to patients to compare prices of cardiovascular (CV) diagnostic studies in US hospitals. Background: In January 2019, CMS mandated that hospitals make prices of CV diagnostic and treatment services available to patients to enable cost comparison. These prices are published in price lists called hospital chargemasters. Methods: We searched hospital chargemasters for the top 20 hospitals listed on the 2020-21 US News Best Hospitals Honor Roll. We collected published price data for six common CV diagnostic studies. Endpoints included listed prices, the format and uniformity of price listings, and accompanying disclaimers or guides for use. Results: Of the 20 studied hospitals, 19 (95%) published a chargemaster on their website, of which 16 were in Microsoft Excel format (84%) and 3 included standardized CPT codes (16%). Disclaimers that prices may not reflect real billing were included with 17 (85%). From available hospital chargemasters (n=19), the following price data were collected. Conclusions: The hospital chargemasters available to compare pricing of CV diagnostic studies show wide variation in price and scope, differ by format, and include technical terms and initialisms. Most include disclaimers that prices may not reflect actual out-of-pocket or insurance billing. These findings suggest that these CMS-mandated price transparency tools may be inadequate for patients to estimate or compare prices for CV diagnostic studies.
Circulating Levels of Ang/Tie2 and VEGF-a Pathway Mediators Are Associated with Clinical Severity, Endothelial Barrier Disruption and Coagulation Activation in COVID-19
Authors: Carla Roberta Peachazepi de Moraes, Ivanio Teixeira de Borba Junior, Franciele de Lima, Mayck Silva Barbosa, Stephany Cares Huber, Andre C. Palma, Thyago A. Nunes, Raisa G. Ulaf, Luciana C. Ribeiro, Ana Flavia Bernandes, Bruna Bombassaro, Sergio S. Dertkigil, Maria Luiza Moretti, Joyce Annichino Bizzacchi, Eli Mansour, Lício Augusto Velloso, Fábio Trindade Maranhão Costa, Fernanda Andrade Orsi, Erich V De Paula
Journal: Blood (2021)
Passage of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act—a Chance to Celebrate and Reflect
Authors: John S. Gill, Richard N. Formica, Barbara Murphy
Journal: Journal of the American Society of Nephrology (2021)

Beginning in 2023, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 5534; also known as the Immuno bill) will add a new Medicare option solely to cover immunosuppressive drugs for kidney transplant recipients.[1][1] Patients may enroll beginning 36 months
Mapping the Multiple Myeloma T Cell Landscape By Immunotherapeutic Perturbation Reveals Mechanism and Determinants of Response to Bispecific T Cell Engagers
Authors: Mirco Friedrich, Paola Neri, Noemie Leblay, Niklas Kehl, Julius Michel, Holly Lee, Elie Barakat, Sungwoo Ahn, Hartmut Goldschmidt, Michael Platten, Niels Weinhold, Marc-Steffen Raab, Nizar J. Bahlis
Journal: Blood (2021)
Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves
Authors: Siaw S. Boon, Martin C. S. Wong, Rita W. Y. Ng, Danny T. M. Leung, Zigui Chen, Christopher K. C. Lai, Wendy C. S. Ho, Junjie Huang, Barry K. C. Wong, Kitty S. C. Fung, Paul K. S. Chan
Journal: JAMA Network Open (2021)

Seroprevalence studies inform the extent of infection and assist evaluation of mitigation strategies for the COVID-19 pandemic.To estimate the prevalence of unidentified SARS-CoV-2 infection in the general population of Hong Kong.A prospective cross-sectional study was conducted in Hong Kong after each major wave of the COVID-19 pandemic (April 21 to July 7, 2020; September 29 to November 23, 2020; and January 15 to April 18, 2021). Adults (age ≥18 years) who had not been diagnosed with COVID-19 were recruited during each period, and their sociodemographic information, symptoms, travel, contact, quarantine, and COVID-19 testing history were collected.The main outcome was prevalence of SARS-CoV-2 infection. SARS-CoV-2 IgG antibodies were detected by an enzyme-linked immunosorbent assay based on spike (S1/S2) protein, followed by confirmation with a commercial electrochemiluminescence immunoassay based on the receptor binding domain of spike protein.The study enrolled 4198 participants (2539 [60%] female; median age, 50 years [IQR, 25 years]), including 903 (22%), 1046 (25%), and 2249 (53%) during April 21 to July 7, 2020; during September 29 to November 23, 2020; and during January 15 to April 18, 2021, respectively. The numbers of participants aged 18 to 39 years, 40 to 59 years, and 60 years or older were 1328 (32%), 1645 (39%), and 1225 (29%), respectively. Among the participants, 2444 (58%) stayed in Hong Kong since November 2019 and 2094 (50%) had negative SARS-CoV-2 RNA test results. Only 170 (4%) reported ever having contact with individuals with confirmed cases, and 5% had been isolated or quarantined. Most (2803 [67%]) did not recall any illnesses, whereas 737 (18%), 212 (5%), and 385 (9%) had experienced respiratory symptoms, gastrointestinal symptoms, or both, respectively, before testing. Six participants were confirmed to be positive for anti-SARS-CoV-2 IgG; the adjusted prevalence of unidentified infection was 0.15% (95% CI, 0.06%-0.32%). Extrapolating these findings to the whole population, there were fewer than 1.9 unidentified infections for every recorded confirmed case. The overall prevalence of SARS-CoV-2 infection in Hong Kong before the roll out of vaccination was less than 0.45%.In this cross-sectional study of participants from the general public in Hong Kong, the prevalence of unidentified SARS-CoV-2 infection was low after 3 major waves of the pandemic, suggesting the success of the pandemic mitigation by stringent isolation and quarantine policies even without complete city lockdown. More than 99.5% of the general population of Hong Kong remain naive to SARS-CoV-2, highlighting the urgent need to achieve high vaccine coverage.
Association between Hospitalised Vaso-Occlusive Crises and Acute/Chronic Complications in Sickle Cell Disease Patients Aged 16 Years and Older Using the French National Health Insurance Database (SNDS)
Authors: Jean-Benoît Arlet, Hannah Lennon, Miranda Bailey, Eleonore Herquelot, Ludovic Lamarsalle, Fanny Raguideau, Pablo Bartolucci
Journal: Blood (2021)
A cis-acting mechanism mediates transcriptional memory at Polycomb target genes in mammals
Authors: Daniel Holoch, Michel Wassef, Cecilia Lövkvist, Dina Zielinski, Setareh Aflaki, Bérangère Lombard, Tiphaine Héry, Damarys Loew, Martin Howard, Raphaël Margueron
Journal: Nature Genetics (2021)
A multiple 24-hour urine collection study indicates that kidney function decline is related to urinary sodium and potassium excretion in patients with chronic kidney disease
Authors: Soshiro Ogata, Yuumi Akashi, Takaya Sakusabe, Shigehito Yoshizaki, Yuko Maeda, Kunihiro Nishimura, Kenji Maeda, Shigeru Nakai
Journal: Kidney International (2021)

Multiple 24-hour urine collections are necessary to adequately assess sodium and potassium intake. Here, we assessed kidney function decline for four years after baseline in relation to seven-time averaged 24-hour urinary sodium and potassium excretion (UNaV, UKV), their UNaV/UKV ratio, and their categorical combination in outpatients with chronic kidney disease (CKD). This retrospective cohort study was based on 240 outpatients with baseline CKD stages 3-5, baseline age 20 years or more (median age 72.0 years), and a median follow-up (with interquartile range) of 2.9 (1.4-4.0) years. Outcome was the percentage change in annual slope of estimated glomerular filtration rate (delta eGFR per year). In linear mixed models, percentage changes in delta eGFR per year were -3.26% (95% confidence interval -5.85 to -0.60), +5.20% (2.34 to 8.14), and -5.20% (-7.64 to -2.69), respectively, per one standard deviation increase in the seven-time averaged UNaV and UKV, and their UNaV/UKV ratio. Additionally, percentage changes per year in delta eGFR per year were -16.27% (-23.57 to -8.27) in the middle-to-high UNaV and low UKV group, compared with the low UNaV and middle-to high UKV group. Thus, our study reinforces the observation of opposite associations between GFR decline and urinary excretion rates of sodium (positive) and potassium (negative), respectively. Whether changes in dietary sodium and potassium intake slow GFR decline still requires further study.
Injectable conductive gelatin methacrylate / oxidized dextran hydrogel encapsulating umbilical cord mesenchymal stem cells for myocardial infarction treatment
Authors: Shuoji Zhu, Changjiang Yu, Nanbo Liu, Mingyi Zhao, Zerui Chen, Jian Liu, Ge Li, Huanlei Huang, Huiming Guo, Tucheng Sun, Jimei Chen, Jian Zhuang, Ping Zhu
Journal: Bioactive Materials (2021)

Umbilical cord mesenchymal stem cells (UCMSCs) transplantation has been proposed as a promising treatment modality for myocardial infarction (MI), but the low retention rate remains a considerable challenge. Injectable natural polymer hydrogels with conductivity ability are highly desirable as cell delivery vehicles to repair infarct myocardium and restore the cardiac function. In this work, we developed a hydrogel system based on gelatin methacrylate (GelMA) and oxidized dextran (ODEX) as cell delivery vehicles for MI. And dopamine could be used as a reductant of graphene oxide (GO) to form reductive GO (rGO). By adjusting the amount of rGO, the conductivity of hydrogels with 0.5 mg/mL rGO concentration (≈10-4 S/cm) was similar to that of natural heart tissue. In vitro cell experiments showed that the prepared hydrogels had excellent biocompatibility and cell delivery ability of UCMSCs. More importantly, GelMA-O5/rGO hydrogel could promote UCMSCs growth and proliferation, improve the myocardial differentiation ability of UCMSCs, and up-regulate the expression of cTnI and Cx43. Further in vivo experiments demonstrated that GelMA-O5/rGO/UCMSCs Hydrogel could significantly improve the ejection fraction (EF) of rats and significantly reduce myocardial infarct area compared to PBS group, promote the survival of UCMSCs, enhance the expression level of cTnI and Cx43, and decrease the expression level of caspase-3. The findings of this study suggested that the injectable conductive GelMA-O5/rGO hydrogel encapsulating UCMSCs could improve damaged myocardial tissue and reconstruct myocardial function, which will be a promising therapeutic strategy for cardiac repair.
Flow Cytometry Based Identification of CD26+ Leukemic Stem Cells in the Peripheral Blood Has a Potential Role in the Rapid Diagnosis of Chronic Myeloid Leukemia
Authors: Praveen Sharma, Man Updesh Singh Sachdeva, Shano Naseem, Sreejesh Sreedharanunni, Reena Das, Pankaj Malhotra, Neelam Varma
Journal: Blood (2021)
The Landscape of Immunoglobulin Heavy Chain Gene Repertoire in Lymphoplasmacytic Lymphoma / Waldenström Macroglobulinemia
Authors: Jun Wang, Yuting Yan, Wenjie Xiong, Ge Song, Yi Wang, Zhen Yu, Ying Yu, Jiawen Chen, Yang Jiao, Tingyu Wang, Rui Lv, Qinghua Li, Chengwen Li, Yueshen Ma, Wei Liu, Dehui Zou, Gang An, Qi Sun, Huijun Wang, Zhijian Xiao, Jianxiang Wang, Lugui Qiu, Shuhua Yi
Journal: Blood (2021)
Will The Innovations in Diabetes and Dyslipidemia Affect Our Practice in 2020?
Authors: Cetin Sanlialp Sara
Journal: Clinical Cardiology and Cardiovascular Interventions (2020)

In 2019, new guidelines on arrhythmia, coronary syndrome, diabetes mellitus, hyperlipidemia and pulmonary embolism were published. Innovations and changes in these areas will already affect the practice of cardiologists in 2020. In this article we aimed to focus on these changes and innovations with main lines in diabetes mellitus and hiperlipidemia.
Myeloma Patients with Deletion of 17p: Impact of Tandem Transplant and Clone Size
Authors: Alfredo De La Torre, Eshetu G Atenafu, Adam C. Smith, Vishal Kukreti, Anca Prica, Sita Bhella, Donna E. Reece, Rodger E Tiedemann, Suzanne Trudel, Christine I. Chen
Journal: Blood (2021)
The Collaborative Community on Ophthalmic Imaging: Accelerating Global Innovation and Clinical Utility
Authors: Mark S. Blumenkranz, Michelle E. Tarver, David Myung, Malvina B. Eydelman, Mark S. Blumenkranz, Malvina B. Eydelman, Michael D. Abràmoff, Emily Chew, Michael F. Chiang, Aaron Lee, David Myung, Michael Repka, Joel S. Schuman, Carol Shields, Michelle E. Tarver
Journal: Ophthalmology (2021)
COVID-19 Is Associated with Endothelial Dysfunction and Enhanced Plasma Thrombin Generation Despite Pharmacological Thromboprophylaxis
Authors: Sarah Kelliher, Luisa Weiss, Sarah Cullivan, Ellen O' Rourke, Claire Murphy, Shane Toolan, Shane Comer, Paulina Szklanna, Aine Lennon, Hayley MacCleod, Sean Gaine, Katherine O' Reilly, John Stack, Ana Le Chevillier, Brian McCullagh, Patricia Maguire, Fionnuala Ni Ainle, Barry Kevane
Journal: Blood (2021)
Flow Cytometric Detection of Procoagulant Properties of Plasma from Patients with Clinically Confirmed Vaccine-Induced Immune Thrombotic Thrombocytopenia
Authors: Christine Shu Mei Lee, Agnibesh Dey, Heather Campbell, Emmanuel J Favaloro, Lisa Clarke, Freda H. Passam, Timothy Brighton, Vivien Chen
Journal: Blood (2021)
CD30-Directed Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Hodgkin Lymphoma and Non-Hodgkin Lymphoma in Pediatric Patients
Authors: George E. Hucks, Barbara Savoldo, Gianpietro Dotti, Catherine Joyce Arago Cheng, Caroline Babinec, Kimberly A. Kasow, Michael Winstead, Arpita Patel, Cammie Presler, Natalie S Grover, J. Kaitlin Morrison, Anne W. Beaven, Marcie L. Riches, Thomas C. Shea, Jonathan S. Serody
Journal: Blood (2021)
Higher Expression of TREM-2 on M-MDSC Cell Surface Independently Predicts Worse Survival in Adults with Newly-Diagnosed and Treatment-Naïve Non-Hodgkin Lymphoma
Authors: Hao-Yuan Wang, Fu-Chen Yang, Yao-Chung LIU, Po-Shen Ko, Ching-Fen Yang, Nien-Jung Chen
Journal: Blood (2021)